SEP 14, 2020 5:46 AM PDT

The Immune System Can Kill HIV with a Helper Molecule

WRITTEN BY: Carmen Leitch

HIV is an insidious virus that has incredible survival abilities. It attacks the human immune system's CD4 cells, a major player in the body's defense against pathogens. While drugs that suppress the virus have been developed, it is still able to hide away in the genome, ready to emerge at any time and cause illness. If a case of HIV is going to be completely cured, those latent viral reservoirs have to be destroyed. Otherwise, HIV patients have to continue to take medications that keep the virus at bay.

"If they ever stop, in short order the virus rebounds and resets at the high levels seen before starting, and that seems to be the case even after decades of therapy," said Mark Painter, Ph.D., a graduate student in the University of Michigan Medical School's department of microbiology and immunology.

Decades ago, researcher Kathleen Collins, M.D., Ph.D., found that HIV can use a protein called Nef to interfere with a cell-surface protein, MHC-1, that would normally tell the immune system that a cell is infected with a pathogen and has to be eliminated. Nef disables MHC-1, and infected cells can keep dividing. Researchers led by Collins wanted to target Nef.

First, they looked for a drug that could target Nef and was already approved. This would theoretically restore the normal action of MHC-1, and the immune system could then use cytotoxic T lymphocytes as it normally would to identify and destroy cells infected with HIV.

"We started out screening a library of 200,000 small molecules and found none inhibited Nef," said Painter. They sought assistance from the lab of David Sherman, Ph.D. of the U-M Life Sciences Institute, where researchers study the biosynthesis of natural products from microbes.

"Often synthetic molecules have quite a low molecular weight, meaning they are fairly small. And if you need to disrupt a large protein surface or interface, such as with Nef, a small molecule won't work well or at all," said Sherman. "A natural products library like the one at the LSI, on the other hand, is going to have molecules with a large range of weights and sizes."

They screened about 30,000 molecules to find a class of antibiotic molecules called pleicomacrolides that could inhibit Nef.

An SEM image of a single, red-colored, H9-T cell infected by numerous, spheroid shaped, mustard-colored human immunodeficiency virus (HIV) particles, seen attached to the cell's surface membrane./ Credit: National Institute of Allergy and Infectious Diseases (NIAID)

"Pleicomacrolides are widely used in lab experiments when you want to shut down the lysosome. Because of this, they are considered toxic and risky to use as drugs," said Painter.

The cell uses an organelle called the lysosome to break down degraded or unwanted parts. One pleicomacrolide, concanamycin A, can inhibit Nef without inhibiting the lysosome if it's used at the right concentration. In a cell culture model, HIV-infected cells that express Nef were eliminated by cytotoxic T cells after concanamycin A exposure. The findings have been reported in the Proceedings of the National Academy of Sciences.

 "As a lead compound for drug development, it's fairly exciting because we can use a very low dose, and inhibit Nef without short-term toxicity to the cells," said Painter.

"It's been extremely gratifying for this project, which began in my lab over a decade ago to finally come to fruition. I had hoped we would find something that worked as well as this compound does but it was never a guarantee that we would actually be successful. This type of research is risky but extremely important because of the potential reward," said Collins. She cautioned that the drug is not ready for use in patients yet. "More research will be needed to optimize the compound. We will need to further separate the potent Nef inhibitory activity from the more toxic effect on lysosomal function to make it a viable therapy."


Sources: AAAS/Eurekalert! via Michigan Medicine, Proceedings of the National Academy of Sciences

About the Author
BS
Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
MAY 12, 2022
Drug Discovery & Development
Gut Bacteria Composition Predicts Resposnse to Statins
MAY 12, 2022
Gut Bacteria Composition Predicts Resposnse to Statins
The composition of the gut microbiome is predictive of patient responses to statins. The corresponding study was publish ...
JUN 08, 2022
Clinical & Molecular DX
Researchers Search for a Treatment for a Lethal Clostridium Bacteria
JUN 08, 2022
Researchers Search for a Treatment for a Lethal Clostridium Bacteria
Clostridium bacteria are a normal component of the gut microbiome. In rare cases, dysbiosis of Clostridium in the body c ...
AUG 11, 2022
Cell & Molecular Biology
From sample collection straight to RT-qPCR
AUG 11, 2022
From sample collection straight to RT-qPCR
Skip the nucleic acid purification step in your cancer detection workflow. Learn more about how Thermo Fisher Scientific ...
JUN 08, 2022
Coronavirus
How are you Preparing for the Next Covid Surge?
JUN 08, 2022
How are you Preparing for the Next Covid Surge?
After two years of uncertainty, we can definitely say that the coronavirus (Covid-19) has changed our everyday lives as ...
JUN 20, 2022
Cannabis Sciences
Weed and your lungs: The latest information
JUN 20, 2022
Weed and your lungs: The latest information
How does cannabis affect your lungs? More research is coming out - here's the latest info.
JUL 28, 2022
Immunology
The Impact of One Gut Microbe on Human Immunity is Deciphered
JUL 28, 2022
The Impact of One Gut Microbe on Human Immunity is Deciphered
Since researchers began to examine it in detail, the gut microbiome has been associated with myriad aspects of human hea ...
Loading Comments...